Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan-Reference-Cited by-同舟云学术

Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan

Published:2022-02 Issue: Volume:Volume 18 Page:363-373
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Watanabe Koichiro^ORCID,Fujimoto Shinji^ORCID,Marumoto Tatsuro,Kitagawa Tadayuki,Ishida Kazuyuki,Nakajima Tadashi,Moriguchi Yoshiya^ORCID,Fujikawa Keita,Inoue Takeshi^ORCID

Publisher

Informa UK Limited

Reference49 articles.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.

2. Anhedonia in Unipolar Major Depressive Disorder: A Review~!2009-10-26~!2010-02-18~!2010-04-08~!

3. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms

4. Dimensions in major depressive disorder and their relevance for treatment outcome

5. Reconsidering anhedonia in depression: Lessons from translational neuroscience

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review;Psychiatry Research;2024-10

2. The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature;Journal of Clinical Medicine;2024-01-17

3. Psychometric properties of the Clinical Assessment Interview for Negative Symptoms (CAINS) in patients with depression and its relationship to affective symptoms;Annals of General Psychiatry;2023-10-26

4. Anhedonia and Depressive Disorders;Clinical Psychopharmacology and Neuroscience;2023-08-31

5. Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial;Neuropsychopharmacology Reports;2023-06-27